Kisspeptin-10 testing round-up: what our latest samples measured
What the published research on Kisspeptin-10 does and does not establish.
The Peptide Institute Testing Desk··9 min read
Kisspeptin-10 is a hypothalamic neuropeptide fragment with a development status of "phase 2 clinical trials". The Institute rates the strength of its published evidence as moderate. An upstream regulator of GnRH release, studied in reproductive endocrinology and in hypoactive sexual desire.
This report covers the Kisspeptin-10 samples processed in our most recent testing cycle. Every specimen was purchased anonymously at retail, transferred under chain-of-custody documentation, and analysed by an independent contract laboratory.
The Peptide Institute is an independent research institute. We do not sell products, we do not accept vendor sponsorship, and we publish results that reflect badly on companies as readily as results that do not.
224 independent tests across 20 companies and 55 compounds. The industry is bifurcating, and the gap is measurable.
Institute Investigation
Free download
Get the free Peptide Playbook, plus new breakthroughs as they happen.
What peptides are, why people are using them, and what results people are talking about,
in plain English. Sign up and we email you the Playbook right away.
